Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Regeneron Pharmaceuticals Inc., 3 years.
Regeneron Pharmaceuticals Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 4, 2024 | Regeneron Pharmaceuticals Inc. | Gift | −1,200 | — | — |
| May 3, 2024 | Regeneron Pharmaceuticals Inc. | Option exercise | +2,000 | $413.33 | $826,660 |
| May 3, 2024 | Regeneron Pharmaceuticals Inc. | Shares withheld for tax | −877 | $942.53 | $826,599 |
| Feb 26, 2024 | Regeneron Pharmaceuticals Inc. | Option exercise | +500 | $413.33 | $206,665 |
| Feb 26, 2024 | Regeneron Pharmaceuticals Inc. | Open-market sale | −500 | $990.00 | $495,000 |
| Feb 26, 2024 | Regeneron Pharmaceuticals Inc. | Option exercise | +500 | $413.33 | $206,665 |
| Feb 26, 2024 | Regeneron Pharmaceuticals Inc. | Open-market sale | −500 | $995.00 | $497,500 |
| Feb 23, 2024 | Regeneron Pharmaceuticals Inc. | Option exercise | +500 | $413.33 | $206,665 |
| Feb 23, 2024 | Regeneron Pharmaceuticals Inc. | Open-market sale | −500 | $985.00 | $492,500 |
| Feb 22, 2024 | Regeneron Pharmaceuticals Inc. | Option exercise | +1,000 | $413.33 | $413,330 |
| Feb 22, 2024 | Regeneron Pharmaceuticals Inc. | Open-market sale | −1,000 | $970.00 | $970,000 |
| Feb 22, 2024 | Regeneron Pharmaceuticals Inc. | Option exercise | +1,000 | $413.33 | $413,330 |
| Feb 22, 2024 | Regeneron Pharmaceuticals Inc. | Open-market sale | −1,000 | $965.00 | $965,000 |
| Feb 22, 2024 | Regeneron Pharmaceuticals Inc. | Option exercise | +1,000 | $413.33 | $413,330 |
| Feb 22, 2024 | Regeneron Pharmaceuticals Inc. | Open-market sale | −1,000 | $960.00 | $960,000 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.